Stay updated with breaking news from Jonathan Ledermann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH.
Cervical cancer is most commonly diagnosed in women in their early 30s, with about 3,200 new cases each year in the UK. It is also the fourth most common cancer among women globally.
A simple change to cervical cancer treatment using already approved drugs has shown the biggest improvement in survival rates in decades.
The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could reduce the rate of relapse and death among patients with locally advanced cervical cancer.
<p>A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH at the<strong> </strong>European Society for Medical Oncology (ESMO) Congress 2023.</p>